American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Cellectis S.A.

$2.93 -4.25% NASDAQ: CLLS · 15-min delayed

Public · NASDAQ: CLLS
229 employees

Visit website Follow

$307.9MMarket cap

229Employees

CLLSNASDAQ

2015IPO

About Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Company facts

Type: Public · NASDAQ: CLLS
Employees: 229
IPO date: Mar 25, 2015
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: CLLS Nasdaq
SEC CIK: 1627281
SIC: 2836 Biological Products, (No Diagnostic Substances)

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow Cellectis S.A. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Market cap: $307.9M

NASDAQ: CLLS

$2.93 -4.25%

15-minute delayed · data by Polygon.io

Past year

$1.33 $5.35

52-week range

Market cap: $307.9M
Shares outstanding: 105.1M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Mar 25, 2015

Market data by Polygon.io · prices are 15-minute delayed

Auto-generated

At a glance

Trading 45% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Cellectis S.A..

Write a review